RTP Mobile Logo

Friday, December 6, 2019, Orlando, Florida, 6:00 PM – 9:00 PM

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenström Macroglobulinemia (Part 2 of a 2-Part Series)

A Friday Satellite Symposium Preceding the 61st ASH Annual Meeting

This activity, the second of a 2-part series, will focus on common practical issues and challenges faced by clinicians caring for patients with multiple myeloma and the related disorders Waldenström macroglobulinemia and amyloidosis. Six world-renowned investigators will serve as the faculty. Leading up to the event, Research To Practice will recruit community-based medical and hematologic oncologists to participate in a unique assessment to identify specific challenging clinical situations or questions they have related to the management of these diseases for which they would seek investigator input. The live event will be divided into 6 distinct topic modules, each featuring a discussion of the questions and issues presented by the consulting clinicians and a faculty member-led review of relevant ongoing research. To cultivate a more interactive experience, clinicians in attendance will utilize networked iPads® to complete an onsite survey featuring a number of the same questions and topics to be discussed, the results of which will be presented and discussed throughout the program.

Event Details

Location
Hilton Orlando
6001 Destination Parkway
Orlando, FL 32819
Hotel Phone: (407) 313-4300

Time
6:00 PM – 6:30 PM — Registration and Dinner Buffet
6:30 PM – 9:00 PM — Educational Meeting

Meeting Room
Orange Ballroom (Lower Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty
Jesús G Berdeja, MD
Director of Myeloma Research
Sarah Cannon Research Institute
Nashville, Tennessee

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

María-Victoria Mateos, MD, PhD
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Nikhil C Munshi, MD
Professor of Medicine, Harvard Medical School
Director of Basic and Correlative Science
Associate Director
Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts


Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer
Research Professor
Department of Lymphoma and Myeloma
Professor
Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida



Agenda

Event Time
6:00 PM – 6:30 PM — Registration and Dinner Buffet
6:30 PM – 9:00 PM — Educational Meeting

MODULE 1: Up-Front Management of Multiple Myeloma (MM) — Dr Raje

  • Current criteria for the diagnosis of active versus smoldering MM; indications for and selection of therapeutic intervention
  • Evidence-based selection of induction therapy for patients with normal- and high-risk disease who are eligible and ineligible for transplant
  • Published research findings with and current clinical role of novel front-line treatment regimens (RVD lite, carfilzomib/lenalidomide/dexamethasone, daratumumab/bortezomib/thalidomide/dexamethasone, daratumumab/lenalidomide/dexamethasone)
  • Available data with and ongoing clinical trials evaluating novel induction approaches (eg, ENDURANCE, GRIFFIN, GMMG-HD6)
  • Current role of bone-directed therapy for patients with and without documented lytic involvement; patient selection for treatment with denosumab

MODULE 2: Consolidation and Maintenance Therapy; Emerging Role of Minimal Residual Disease (MRD) — Dr Munshi

  • Clinical and biologic factors (eg, high-risk features, t(4;14), response to induction therapy) that affect the selection of optimal maintenance approach
  • Long-term risks associated with the use of extended maintenance therapy with lenalidomide and/or bortezomib; duration of therapy and current use of treatment breaks
  • Design, eligibility criteria and key efficacy and safety outcomes from the Phase III TOURMALINE-MM3 trial comparing ixazomib to placebo as maintenance therapy after autologous stem cell transplant; indications, if any, for the use of ixazomib maintenance outside of a clinical trial setting
  • Clinical significance of MRD; current and potential role to inform decision-making, including the need for and duration of maintenance therapy
  • Limitations and advantages of commercially available MRD testing platforms

MODULE 3: Current Management of Relapsed/Refractory (R/R) MM — Dr Mateos

  • Impact of prior therapeutic exposure, disease-free interval, cytogenetic status and symptomatology on therapeutic decision-making for patients with R/R MM
  • Incorporation of carfilzomib and pomalidomide into current MM treatment algorithms; indications for combination-based approaches and optimal therapeutic partners
  • Research database supporting the FDA approvals of daratumumab-, elotuzumab- and ixazomib-based regimens for patients with R/R disease
  • Results of the Phase IIB STORM trial leading to the FDA approval of the combination of selinexor and dexamathesone for patients who have received at least 4 prior therapies for MM
  • Optimal sequencing of therapies for R/R MM in current clinical practice

MODULE 4: Novel Strategies Under Investigation for the Treatment of MM — Dr Lonial

  • Biologic rationale for and early safety and efficacy data with venetoclax in patients with and without t(11;14) MM
  • Rates of tumor lysis syndrome and other notable adverse events with the use of venetoclax in MM
  • Ongoing Phase III investigation of venetoclax and potential clinical role, particularly in patients with t(11;14) MM
  • Mechanism of action of and early research experience with isatuximab; structural and pharmacologic similarities and differences between isatuximab and daratumumab
  • Available data from the Phase III ICARIA-MM trial evaluating pomalidomide and low-dose dexamethasone with or without isatuximab for patients with R/R MM; current developmental timeline, potential role in clinical practice and other ongoing trials with isatuximab
  • Other promising agents and strategies under investigation

MODULE 5: Therapeutic Strategies Targeting B-Cell Maturation Antigen (BCMA) in MM — Dr Berdeja

  • Compositional and mechanistic variations among BCMA-targeted chimeric antigen receptor (CAR) T-cell platforms under investigation in MM (eg, bb2121, bb21217, JCARH125, LCAR-B38M, MCARH171)
  • Published research experience with BCMA-targeted CAR T-cell therapies in MM; similarities and differences between trial designs, patient populations, dosing strategies and efficacy and safety outcomes
  • Current developmental timeline for and ongoing clinical trials of CAR T-cell therapy in MM
  • Rationale for the use of bispecific T-cell engagers (BiTEs) to target BCMA and CD3 in patients with MM; available safety and efficacy data with and ongoing and planned clinical trials of BiTEs in patients with R/R MM
  • Mechanism of action of and available data with the BCMA-directed antibody-drug conjugate belantamab mafodotin; FDA breakthrough therapy designation and ongoing evaluation

MODULE 6: Amyloidosis (AL) and Waldenström Macroglobulinemia (WM) — Dr Orlowski

  • Evidence-based use of various systemic approaches (chemotherapy, proteasome inhibitors, IMiDs, et cetera) in the up-front treatment of primary AL
  • Emerging data with daratumumab in patients with treatment-refractory AL; current off-protocol role
  • Diagnosis, risk stratification and indications for therapeutic intervention in patients with WM
  • Management of treatment-naïve WM; available data with and FDA approval of ibrutinib/rituximab
  • Published research findings with and ongoing clinical trials of novel agents and strategies (eg, acalabrutinib, carfilzomib, ixazomib) in WM

CE Information

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM), Waldenström macroglobulinemia (WM) and amyloidosis.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for multiple myeloma (MM) in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Appreciate available clinical trial data documenting the efficacy of monoclonal antibody therapy directed at CD38 as a component of induction therapy, and effectively identify whether and how this strategy should be integrated into the clinical care of patients eligible or ineligible for stem cell transplant.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory MM.
  • Appreciate available data documenting the activity of CAR T-cell therapy, bispecific T-cell engagers and antibody-drug conjugates designed to target B-cell maturation antigen (BCMA), and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches as part of a clinical trial.
  • Design and implement a plan of care for patients with smoldering MM, considering the applicability of existing and emerging clinical trial data.
  • Consider clinical and other patient-related factors in the selection and sequencing of systemic therapy for patients with WM and primary amyloidosis.
  • Assess the ongoing clinical trials evaluating novel investigational approaches for MM, WM and amyloidosis, and obtain consent from appropriate patients for study participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Location

Hilton Orlando
6001 Destination Parkway
Orlando, FL 32819
Hotel Phone: (407) 313-4300

Meeting Room
Orange Ballroom (Lower Level)

Directions
The Hilton Orlando hotel is conveniently located within walking distance of the Orange County Convention Center, where the ASH Annual Meeting is taking place.

 

Registration

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma, Waldenström macroglobulinemia and amyloidosis.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.